CNBC June 30, 2021
Ian Thomas

Key Points

– CRISPR gene editing, which slices DNA to treat diseases, had its first-ever systemic delivery in a human body.

– Jennifer Doudna, who won the 2020 Nobel Prize in chemistry for her work on CRISPR, called the early success of the technology “one of the fastest rollouts I think of technology from the fundamental, initial science to an actual application.”

– Intellia Therapeutics, the biotech she co-founded, has seen its stock rise over 100% this month.

Gene-editing technology CRISPR reached a major milestone this past weekend, completing its first systemic delivery as a medicine to a human body.

CRISPR, or clustered regularly interspaced short palindromic repeats, effectively cuts genomes and slices DNA to treat genetic diseases.

The latest...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech, Precision Medicine
Brazil’s plan for low-cost CAR-Ts
PacBio’s Repeat Expansion Panel, Owkin-Sanofi AI Take on Immunology, More
STAT+: Borrowing an idea from cancer immunotherapy, scientists make old-mice immune systems youthful again
Moderna gets Blackstone backing for flu vaccine R&D
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension

Share This Article